Audentes Therapeutics Inc. (BOLD)’s Financial Results Comparing With Capricor Therapeutics Inc. (NASDAQ:CAPR)

Audentes Therapeutics Inc. (NASDAQ:BOLD) and Capricor Therapeutics Inc. (NASDAQ:CAPR) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Audentes Therapeutics Inc. N/A 0.00 128.82M -2.72 0.00
Capricor Therapeutics Inc. 1.67M 11.58 15.19M -0.11 0.00

Table 1 demonstrates Audentes Therapeutics Inc. and Capricor Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 represents Audentes Therapeutics Inc. (NASDAQ:BOLD) and Capricor Therapeutics Inc. (NASDAQ:CAPR)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Audentes Therapeutics Inc. 0.00% -36.6% -33.9%
Capricor Therapeutics Inc. -909.58% 3.9% 2.6%


The Current Ratio of Audentes Therapeutics Inc. is 14.8 while its Quick Ratio stands at 14.8. The Current Ratio of rival Capricor Therapeutics Inc. is 6.1 and its Quick Ratio is has 6.1. Audentes Therapeutics Inc. is better equipped to clear short and long-term obligations than Capricor Therapeutics Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Audentes Therapeutics Inc. and Capricor Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Audentes Therapeutics Inc. 0 0 0 0.00
Capricor Therapeutics Inc. 0 0 1 3.00

Capricor Therapeutics Inc. on the other hand boasts of a $3.5 average target price and a 508.70% potential upside.

Insider and Institutional Ownership

Audentes Therapeutics Inc. and Capricor Therapeutics Inc. has shares owned by institutional investors as follows: 0% and 5.4%. About 1.3% of Audentes Therapeutics Inc.’s share are owned by insiders. Comparatively, insiders own roughly 35.68% of Capricor Therapeutics Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Audentes Therapeutics Inc. 18.9% 40.28% 43.46% -2.66% 2.02% 63.18%
Capricor Therapeutics Inc. 11.49% -4.62% -40.85% -59.58% -71.97% 18.29%

For the past year Audentes Therapeutics Inc.’s stock price has bigger growth than Capricor Therapeutics Inc.


Capricor Therapeutics Inc. beats Audentes Therapeutics Inc. on 7 of the 10 factors.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The companyÂ’s development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.